Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals' revenue rose 60.1% to $678 million in fiscal 2025. Its operating margin was 11.4%, up from −10.8% a year earlier. Free cash flow was $136 million, up 436.8%. The diluted share count rose 10.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Kiniksa Pharmaceuticals does
Kiniksa Pharmaceuticals develops and sells medicines for diseases with unmet needs, mainly heart-related. Its one commercial product is ARCALYST, a protein that blocks two inflammation signals, interleukin-1 alpha and beta. It licensed ARCALYST from Regeneron in 2017 with worldwide rights, excluding the Middle East and North Africa, for uses other than cancer and local treatment of the eye or ear.
The U.S. Food and Drug Administration approved ARCALYST for recurrent pericarditis (a painful inflammation of the sac around the heart) in 2021. It is also approved in the U.S. for two rare inflammatory conditions. Kiniksa sells it in the United States through a select network of specialty pharmacies and handles all sales and distribution. It splits profits on sales evenly with Regeneron. It gave a Chinese company, Huadong, rights to develop and sell it in that company's territory.
Regeneron began transferring its manufacturing process, and Kiniksa is working to qualify Samsung as its new contract manufacturer.
Its biggest risks, as it describes them
- It may not keep up commercial success with ARCALYST, its sole product, or succeed with future products.
- It relies on a select network of specialty pharmacies to market and sell ARCALYST.
- Insurers and government payors may not cover or pay enough for its medicines, and drug-price policy could limit prices.
- It derives substantially all of its revenue from one use in the United States.
- Its candidates may not advance in clinical development or win regulatory approval.
Income statement
From fiscal 2022 to 2025, earnings per share fell 33.9% a year and net income 31.5% a year, as new shares raised the share count by 12% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 182 | 191 | 206 | 244 | 414 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.4x | 5.2x | 4.3x | 3.3x | 3.8x |
| Quick ratio | 4.3x | 4.7x | 3.9x | 3.0x | 3.4x |
Cash flow
Projections
Project Kiniksa Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Kiniksa Pharmaceuticals shares on the open market, and 8 insiders sold $45.1 million, $44.8 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | Michael R MegnaChief Accounting Officer | Sold plan | 11,280 | $98.54 | $1.1 million | Form 4 |
| Sep 3, 2026 | Michael R MegnaChief Accounting Officer | Sold plan | 4,600 | $80.30 | $369,380 | Form 4 |
| Jul 29, 2026 | Cole G BradleyDirector | Sold | 3,673 | $81.43 | $299,092 | Form 4 |
| May 1, 2026 | John F. PaoliniChief Medical Officer | Sold plan | 58,424 | $53.71 | $3.1 million | Form 4 |
| May 1, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 48,565 | $54.02 | $2.6 million | Form 4 |
| Apr 30, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 2,141 | $54.01 | $115,635 | Form 4 |
| Apr 29, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 22,544 | $54.01 | $1.2 million | Form 4 |
| Apr 28, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 483,654 | $51.86 | $25.1 million | Form 4 |
| Apr 28, 2026 | Barry D QuartDirector | Sold plan | 13,099 | $50.10 | $656,260 | Form 4 |
| Apr 9, 2026 | Michael R MegnaChief Accounting Officer | Sold plan | 6,625 | $46.69 | $309,321 | Form 4 |
| Apr 9, 2026 | Ross MoatChief Operating Officer | Sold plan | 1,703 | $46.69 | $79,513 | Form 4 |
| Apr 6, 2026 | Sanj K PatelChairman & CEO, Director | Sold plan | 7,278 | $50.01 | $363,973 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 27.6% | 62.6% | 80.2% |
| Altman Z'' | 4.64 | 2.40 | 5.08 |
| Accruals ratio | 0.2% | −12.4% | −11.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Kiniksa Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals | FY25 | 60.1% | 11.4% | 20.1% | — | — | — | |
| Ultragenyx Pharmaceutical | FY25 | 20.2% | −79.5% | −70.1% | — | — | — | Compare |
| Amphstar Pharmaceuticals | FY25 | −1.6% | 19.5% | 16.8% | 9.9% | 1.7x | 6 | Compare |
| Pacira BioSciences | FY25 | 3.6% | 2.6% | 18.8% | 1.1% | 1.2x | 9 | Compare |
| OPKO Health | FY25 | −14.9% | −19.4% | −31.4% | −7.0% | — | 4 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | — | — | 38 | 220 | 270 | 423 | 678 |
| Revenue growth | — | — | — | — | — | 471.2% | 22.7% | 56.6% | 60.1% |
| Gross profit | — | — | — | — | 29 | 197 | 237 | 362 | 600 |
| Research and development | 56 | 87 | 135 | 112 | 99 | 66 | 76 | 112 | 97 |
| Operating income | −65 | −108 | −170 | −157 | −157 | 10 | −25 | −46 | 77 |
| Net income | −65 | −103 | −162 | −161 | −158 | 183 | 14 | −43 | 59 |
| Diluted EPS (US$) | −35.85 | −3.49 | −2.99 | −2.61 | −2.30 | 2.60 | 0.20 | −0.60 | 0.75 |
| Diluted shares (millions) | 2 | 30 | 54 | 62 | 69 | 70 | 72 | 71 | 79 |
| Cash flow | |||||||||
| Cash from operations | −50 | −81 | −158 | −136 | −126 | 6 | 13 | 26 | 138 |
| Capital expenditure | 0 | 5 | 3 | 0 | 0 | 0 | 0 | 0 | 2 |
| Free cash flow | −50 | −86 | −162 | −137 | −127 | 6 | 13 | 25 | 136 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 6 | 15 | 21 | 25 | 25 | 27 | 31 | 37 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 46 | 307 | 233 | 324 | 182 | 191 | 206 | 244 | 414 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — |
| Total assets | 48 | 322 | 254 | 350 | 233 | 460 | 526 | 581 | 764 |
| Total liabilities | 17 | 43 | 29 | 38 | 48 | 64 | 88 | 142 | 196 |
| Shareholders' equity | −90 | 279 | 225 | 312 | 185 | 396 | 439 | 438 | 568 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% |
| Operating margin | — | — | — | — | −406.4% | 4.4% | −9.3% | −10.8% | 11.4% |
| Net margin | — | — | — | — | −409.7% | 83.3% | 5.2% | −10.2% | 8.7% |
| Free cash flow margin | — | — | — | — | −328.8% | 2.6% | 4.9% | 6.0% | 20.1% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | 473.8% | 27.6% | 62.6% | 80.2% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −108.9% | −64.2% | −60.1% | −63.5% | 63.1% | 3.4% | −9.8% | 11.7% |
| Return on assets | — | −55.9% | −56.2% | −53.4% | −54.2% | 53.0% | 2.9% | −7.8% | 8.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |